SCHEMBL2415802

SCHEMBL2415802

CC(C)C(=O)OC1CCC=CCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.43
CYP2D6 P10635 3/20 0.33
LMNA P02545 2/20 0.33
CHRM2 P08172 2/20 0.33
CHRM4 P08173 2/20 0.33
CHRM5 P08912 2/20 0.33
THRB P10828 2/20 0.33
CHRM1 P11229 2/20 0.33
CHRM3 P20309 2/20 0.33
BLM P54132 2/20 0.33
PMP22 Q01453 2/20 0.33
EPHX1 P07099 2/20 0.33
CYP1A2 P05177 2/20 0.33
MEN1 O00255 1/20 0.33
CYP2C9 P11712 1/20 0.33
MTOR P42345 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HTT P42858 1/20 0.33
PTGS1 P23219 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2415798 1.00 CYP19A1 (0.43) CYP19A1CYP2D6LMNACHRM2CHRM4
SCHEMBL2419961 0.84 CYP19A1 (0.50) CYP19A1CYP2D6LMNACHRM2CHRM4
SCHEMBL7915891 0.84 CYP19A1 (0.46) CYP19A1CYP2D6LMNACHRM2CHRM4
SCHEMBL27798319 0.82 CYP19A1 (0.42) CYP19A1CYP2D6LMNACHRM2CHRM4
SCHEMBL26822901 0.82 CYP19A1 (0.53) CYP19A1EPHX1HTTGAANAAA
SCHEMBL753308 0.82 CYP19A1 (0.53) CYP19A1EPHX1HTTGAANAAA
SCHEMBL23054345 0.80 CHRM2 (0.38) CYP19A1CYP2D6CHRM2CHRM1CHRM3
SCHEMBL754296 0.80
SCHEMBL1628386 0.79 EPHX1 (0.38) CYP19A1LMNAEPHX1HTTPTGS1
SCHEMBL31490424 0.79 EPHX1 (0.38) CYP19A1LMNAEPHX1HTTPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260096991-A1 BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION XAMPLA LTD (GB) 2026-04-09 US disclosed
EP-4489592-B1 BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION XAMPLA LTD (GB) 2025-12-24 EP disclosed
US-20250255827-A1 BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION XAMPLA LIMITED (GB) 2025-08-14 US disclosed
EP-4593639-A1 BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION Xampla Limited (GB) 2025-08-06 EP disclosed
US-20250186960-A1 BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION XAMPLA LIMITED (GB) 2025-06-12 US disclosed
EP-3888782-B1 COATED MICROCAPSULES NOXELL CORP (US) 2025-06-11 EP disclosed
US-20250177298-A1 EMULSIONS AND A METHOD FOR THEIR PREPARATION XAMPLA LIMITED (GB) 2025-06-05 US disclosed
WO-2025109106-A1 CORE-SHELL MICROCAPSULES XAMPLA Ltd. (GB) 2025-05-30 WO disclosed
EP-4489592-A1 BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION Xampla Limited (GB) 2025-01-15 EP disclosed
EP-4489717-A1 EMULSIONS AND A METHOD FOR THEIR PREPARATION Xampla Limited (GB) 2025-01-15 EP disclosed
US-20150351519-A1 Articles Providing Long Lasting Fragrances THE PROCTER & GAMBLE COMPANY 2015-12-10 US disclosed
US-20150352575-A1 Articles Providing Long Lasting Fragrances THE PROCTER & GAMBLE COMPANY 2015-12-10 US disclosed
US-20150353867-A1 Articles Providing Long Lasting Fragrances THE PROCTER & GAMBLE COMPANY 2015-12-10 US disclosed
US-20150352578-A1 Flushing Dispensers For Delivering A Consistent Consumer Experience THE PROCTER & GAMBLE COMPANY 2015-12-10 US disclosed
US-20150352576-A1 Dispensers For Delivering A Consistent Consumer Experience THE PROCTER & GAMBLE COMPANY 2015-12-10 US disclosed
EP-2366014-B1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2015-11-04 EP disclosed
US-8754028-B2 Perfume systems THE PROCTER & GAMBLE COMPANY (US) 2014-06-17 US disclosed
EP-2366014-A2 PERFUME SYSTEMS The Procter & Gamble Company (US) 2011-09-21 EP disclosed
US-20100152083-A1 Perfume Systems PROCTER & GAMBLE COMPANY, THE 2010-06-17 US disclosed
WO-2009027957-A2 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260096991-A1 BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION PCTP, CLK4, MTCL3 CYP19A1 4823/4885CYP2D6 4795/4885LMNA 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.